Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (1 week) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Generic quality of life measures · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Economic outcomes · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Smoking cessation · people who smoke
Bupropion plus varenicline showed no clear difference in smoking cessation (at least six months of compared with varenicline alone (moderate certainty).
1 finding from 1 review
Serious adverse events · people who smoke
Bupropion plus varenicline showed no clear difference in serious adverse events compared with varenicline alone (low certainty).
1 finding from 1 review
Dropouts due to treatment · people who smoke
Bupropion plus varenicline showed no clear difference in dropouts due to treatment compared with varenicline alone (low certainty).
1 finding from 1 review
Change in weight (kg) · People who have quit smoking
Varenicline for smoking cessation showed no clear difference in mean weight change (kg) at end of treatment compared with placebo (high certainty).
3 findings from 1 review
MD 0.23
14 studies · 2566 participants
High
MD 0.09
3 studies · 384 participants
Low
MD 1.05
3 studies · 237 participants
Low